We are Janssen. We collaborate with the world for the health of everyone in it.
At Janssen, the pharmaceutical companies of Johnson & Johnson, our mission is to transform individual lives and change fundamentally the way diseases are managed, interpreted, and prevented.
The Johnson & Johnson Medical Devices Companies' purpose is to reach more patients and restore more lives. Having advanced patient care for more than a century, these companies represent an unparalleled breadth of products, services, programs, and research and development capabilities in surgical technology, orthopedics, cardiovascular, and specialty solutions with an offering directed at delivering clinical and economic value to healthcare systems worldwide.
To learn more, please visit us on: https://www.jnjmedicaldevices.com/en-EMEA
Tecnimede Group is composed by pharmaceutical companies of private and 100% Portuguese capital. Started its activity in 1980 and covers the entire life cycle of the medicinal products for human use — development, manufacture, promotion and marketing. Its strategy is based on strong investment in Research, Development, and Production of Medicinal Products.
It is intended that the results obtained allow to consolidate the Group's position in the Portuguese market and to strengthen exports and internationalisation. Atlantic Pharma Brasil and Atlas Pharm (Morocco) are an example of the Group's expansion and development of manufacturing plants. Atlantic Pharma Brasil and Atlas Pharm (Morocco) are an example of the Group's expansion and development of manufacturing plants.
The Tecnimede Group was honoured in the Golden Company category at the 30th edition of the IRG Awards (Investor Relations & Governance Awards), a Deloitte initiative.
The IRG Awards aim to reward outstanding achievements from the previous year in the Portuguese financial and business market.
The Jury presented the Golden Company award this year to the Tecnimede Group based on its assessment that the company excels in the values of management and governance transparency and quality, made patent by the company’s size, performance, international presence and future potential.
Winners were selected by an extensive electoral college comprising representatives from entities operating in the financial and business market, and approved by a panel of judges led by Manuel Alves Monteiro. Other members of jury for this edition included Alberto de Castro, António Gomes Mota, António Saraiva, Esmeralda Dourado, João Duque, Jorge Coelho, Luís Amado, Patrícia Teixeira Lopes and Rui Rio.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @PfizerNews, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.